drugset / Trial / NCT04027348

Palliative Management of Inoperable Malignant Bowel Obstruction

NCT04027348

Phase 2 Terminated 15 enrolled Roswell Park Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

To identify the role of palliative medical management of inoperable malignant bowel obstruction (MBO) with Octreotide, Dexamethasone and Metoclopramide given together as triple therapy.

Timeline

Start
2019-06-26
Primary completion
2021-09-03
Completion
2021-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 4 mg Intravenous
Subject Metoclopramide Small molecule 10 mg Intravenous
Subject Octreotide Peptide 300 ug Intravenous